36330-84-4

Upstream product

• 462-06-6 fluorobenzene 
• 108-98-5 thiophenol 
• 366-77-8 4-(4-fluorophenyl)-4-oxopropionic acid 
• 108-30-5 succinic acid anhydride 
• 139-66-2 diphenyl sulfide 

Downstream Products

• 210972-10-4 7-phenylsulfanyl-3,4-dihydro-2H-naphthalen-1-one 
• 895133-01-4 7-benzenesulfonyl-3,4-dihydro-2H-naphthalen-1-one 
• 6660-34-0 4-(4-phenylsulfanyl-phenyl)-butyric acid 
• 117809-08-2 4-acetylthio-3-<4-(phenylthio)benzoyl>butyric acid 
• 63471-91-0 4-(4-Benzenesulfonyl-phenyl)-4-oxo-butyric acid 
• 63471-92-1 4-(4-Benzenesulfinyl-phenyl)-4-oxo-butyric acid 
• 106144-13-2 3-Acetylsulfanyl-4-oxo-4-(4-phenylsulfanyl-phenyl)-butyric acid ethyl ester 
• 106144-05-2 3-acetylthio-3-(4-phenylthiobenzoyl)propionic acid 
• 117808-94-3 3-<4-(phenylthio)benzoyl>-3-butenoic acid 
• 106144-07-4 3-Benzoylsulfanyl-4-oxo-4-(4-phenylsulfanyl-phenyl)-butyric acid 

Relevant academic research and scientific papers

Arylsulfonyl naphthalene derivatives and uses thereof

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, q, Ar, R1, R2 and R7 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

TETRALIN AND INDANE DERIVATIVES AND USES THEREOF

Compounds of the formula I, II or III; or pharmaceutically acceptable salts thereof, wherein m, n, q, Ar, R1, R2, R3, R4 and R5 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formulas I-III.

TETRALIN AND INDANE DERIVATIVES AND USES THEREOF AS 5-HT ANTAGONISTS

Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R 2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula (I).

TETRALIN AND INDANE DERIVATIVES AND USES THEREOF

Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein R2 is (CR3R4)n-NR5R6 and m, p, q, Ar, R1, R3, R4, R5 and R6 are as defined in the claims, which are selective antagonists of 5-HT6 and/or 5-HT2A. Also provided are compositions comprising these compounds and their use in the preparation of medicaments for treating central nervous system disease states selected from psychoses, schizophrenia, manic depressions, neurological disorders, memory disorders, attention deficit disorder, Parkinson’s disease, amyotrophic lateral scierosis, Alzheimer’s disease, food uptake disorders and Huntington’s disease.

TETRALIN AND INDANE DERIVATIVES AND USES THEREOF

Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein R2 is a group of formula (II) and m, n, p, q, r, Rl and X are as defined in the claims, which are selective agonists of 5-HT6 and 5-HT2A. Also provided are compositions comprising these compounds and methods for their use in the preparation of medicaments for treating central nervous system disease states and disorders of the gastrointestinal tract.

A new non-steroidal anti-inflammatory analgesic: γ-oxo(1,1'-biphenyl)-4-butanoic acid (fenbufen)

100 analogs of γ-oxo(1,1'-biphenyl)-4-butanoic acid (fenbufen) were prepared and tested using the carrageenin, polyarthritis, and UV erythema anti-inflammatory tests and the 2-phenyl-1,4-benzoquinone writhing and inflamed paw pressure analgesic tests. Only three retained the same full spectrum of activity as fenbufen: dl-4-(4-biphenyl)-4-hydroxybutyric acid, dl-4-(4-biphenylyl)-1,4-butanediol, and 4-biphenylacetic acid. Fenbufen had the same spectrum of activity as acetylsalicylic acid (ASA), phenylbutazone, and indomethacin in the five tests. In addition, dose-response derived potencies show fenbufen more potent than ASA and at least as potent as phenylbutazone in all five tests.

Fenbufen, a new anti inflammatory analgesic: synthesis and structure activity relationships of analogs

100 analogs of fenbufen were prepared and tested using the carrageenan, polyarthritis, and UV erythema anti inflammatory tests and the 2 phenyl 1,4 benzoquinone writhing and inflamed paw pressure analgesic tests. Only 3 retained the same full spectrum of activity as fenbufen: dl 4 (4 biphenylyl) 4 hydroxybutyric acid, dl 4 (4 biphenylyl) 1,4 butanediol, and 4 biphenylacetic acid. Fenbufen had the same spectrum of activity as aspirin, phenylbutazone, and indomethacin in the 5 tests. In addition, dose response derived potencies show fenbufen more potent than aspirin and at least as potent as phenylbutazone in all 5 tests. Two related compounds were generally similar.